Xia Kun, Zhou Yaoxiang, Xie Youping, Cai Yinzhong
Department of General Surgery, People's Hospital of Ningxiang City, Ningxiang, Hunan 410600, P.R. China.
Oncol Lett. 2025 Apr 8;29(6):282. doi: 10.3892/ol.2025.15028. eCollection 2025 Jun.
Gastrointestinal cancer is one of the most prevalent malignancies in humans and is often associated with a poor prognosis. Understanding the molecular mechanisms underlying cancer progression and severity is essential for the development of effective cancer therapies. Abnormal protein methylation is associated with the occurrence and advancement of cancer, highlighting the importance of protein methyltransferase research. SET and MYND domain-containing protein 2 (SMYD2), a lysine methyltransferase, has emerged as a promising small molecule target for cancer treatment. Notably, SMYD2 is implicated in the pathogenesis of several diseases, including gastrointestinal cancer. SMYD2 is closely associated with the tumorigenesis, proliferation, migration and other biological processes of gastrointestinal cancer, indicating its potential as a novel therapeutic target. The present review offers an in-depth analysis of SMYD2, covering its structural characteristics, regulatory pathways and functional significance. By assessing the biological roles and therapeutic potential of SMYD2, the current review presents fresh insights and perspectives for advancing research in different types of gastrointestinal cancer.
胃肠道癌是人类中最常见的恶性肿瘤之一，并且通常与预后不良相关。了解癌症进展和严重程度背后的分子机制对于开发有效的癌症治疗方法至关重要。异常的蛋白质甲基化与癌症的发生和发展相关，这凸显了蛋白质甲基转移酶研究的重要性。含SET和MYND结构域蛋白2（SMYD2），一种赖氨酸甲基转移酶，已成为一种有前景的癌症治疗小分子靶点。值得注意的是，SMYD2与包括胃肠道癌在内的几种疾病的发病机制有关。SMYD2与胃肠道癌的肿瘤发生、增殖、迁移及其他生物学过程密切相关，表明其作为新型治疗靶点的潜力。本综述对SMYD2进行了深入分析，涵盖其结构特征、调控途径和功能意义。通过评估SMYD2的生物学作用和治疗潜力，本综述为推进不同类型胃肠道癌的研究提供了新的见解和观点。
